Copy the shared link
Artificial intelligence (AI) is no longer on the horizon – it’s here, and it’s changing the future of medical diagnostics. NVIDIA GTC 2025 (March 17 – March 20) is a global conference bringing together innovators, researchers, and companies from around the world to explore this rapid shift.
One of the key areas of interest is artificial intelligence in medical diagnostics. The GTC AI conference has hundreds of exhibits and technical hands-on training showcasing the latest in medical technology. NOUL attended the conference, presenting our AI-powered miLab™ platforms capable of diagnosing malaria, cervical cancer, and blood disorders. Our participation also included presenting an Edge AI poster, attending meetings with NVIDIA, engaging in discussions within NVIDIA’s Healthcare & Life Sciences (HCLS) ecosystem, and networking with key stakeholders.
NVIDIA GTC 2025 is a major player in the AI space. Little wonder we wanted to demonstrate the possibilities of the miLab™ platform and other innovations. It was a pleasure to talk to so many stakeholders about the benefits of AI in healthcare.
The Benefits of AI in Healthcare
Source: NOUL
AI in medical diagnostics is one promising area of research. Scientists can give the AI datasets of thousands of images, teaching it to identify different aspects of the imagery. Take this further, and the AI can identify malaria-affected blood cells, monitor changes in blood cell morphology, and even diagnose certain cancers.
Once it can identify features accurately within an image, the cost of diagnosis plummets. Doctors can receive a diagnosis in a matter of minutes at a fraction of the cost. This opens the doors to developing and resource-poor countries that lack the healthcare infrastructure to perform complex diagnostics.
NVIDIA GTC 2025: Pioneering AI Innovations in Healthcare
Source: NOUL
NVIDIA GTC 2025 isn’t just a place to talk – companies from all over the world bring their cutting-edge developments to showcase what they’re capable of. Hardly a year goes by without companies revealing their incredible breakthroughs. In fact, NOUL was recognized in 2021 at NVIDIA’s GTC as one of the ‘Top 5 AI Startup Trends’, further cementing its leadership in the AI space. At this year’s conference, NOUL proudly presented our miLab™ platform, which relies on NVIDIA’s chips for groundbreaking medical diagnostics. miLab™ integrates innovative and eco-friendly solid staining technology(NGSI), ensuring consistent and reliable cancer cell staining regardless of the user’s expertise.
This year, NOUL also presented a key abstract at NVIDIA GTC 2025 titled “Bridging Medical Gaps from Malaria to Cancer: On-Device AI Diagnostic Solutions Powered by NVIDIA Jetson.” The abstract highlighted how NOUL’s AI-powered miLab™ platform is bridging the diagnostic gap not only in resource-poor regions but also in developed countries where centralized healthcare facilities create barriers to access. Emphasizing the high mortality rate of cervical cancer, especially in low-income countries, NOUL demonstrated how miLab™ can reduce these disparities with its on-device AI capabilities, offering immediate diagnosis in any setting.
It’s a combination of NVIDIA’s hardware and NOUL’s ingenious software that allows the miLab™ to rapidly identify malaria in blood samples. Already, it’s increasing diagnosis rates and saving lives in endemic regions such as Africa.
Learn more about how NOUL’s point-of-care testing devices are making a difference in the fight against malaria in West Africa.
AI-Driven Diagnostics: The Power of On-Device AI
Source: NOUL
On-device AI is often overlooked in favor of cloud-based technologies. However, NOUL is highlighting the importance of on-device AI for resource-poor regions where access to the internet isn’t a possibility. These low-resource settings require a powerful platform that can provide efficient, accurate diagnostics despite the minimal infrastructure.
There’s no better example than NOUL’s miLab™. Listening to the feedback from the NVIDIA GTC 2025 attendees was remarkable. They praised the integration of NVIDIA’s on-device AI chips for the diagnosis of malaria. This integration allows miLab™ to perform complex analyses on the spot, such as detecting and diagnosing diseases from medical images and test samples with high accuracy.
These devices are being used on the ground, not just to diagnose malaria but also cervical cancer and blood disorders. It’s a lifeline for millions – if not billions – of people globally.
The Future of Healthcare with AI-Powered Diagnostics
Source: NOUL
Well, the outlook for AI in healthcare is exceptionally promising, especially in diagnostics and patient care. The technology is set to become even more sophisticated, with improved algorithms that can predict diseases earlier and with greater precision.
Partnerships, such as that between NVIDIA and NOUL, demonstrate the power of collaboration for AI in medical diagnostics. It’ll be needed if we address the global challenges highlighted by conference attendees. Whether it’s tackling malaria outbreaks, monitoring patient data in real-time, speeding up cancer diagnostics, or surveillance health trends to predict disease spread, AI is an invaluable tool in our arsenal.
Partnering with NOUL for AI-Driven Healthcare Solutions
Source: NOUL
NOUL isn’t just an attendee – our ground-breaking platform, the miLab™, is a real-life example of NVIDIA’s chips in action. AI in medical diagnostics might solve the problem of malaria detection, but there’s still so much more to do.
During the event, Jensen Huang’s 10-minute speech deeply impressed NOUL’s team. As healthcare professionals, we found his message moving, particularly the realization that the impact lies in the hands of the companies using NVIDIA’s AI and healthcare technologies. NVIDIA’s genuine commitment to building an ecosystem stood out to us.
We’re excited to see the future developments. If you want to keep track of NOUL‘s progress and news, please reach out to us. Stay connected with NOUL on LinkedIn to get the latest updates on our AI-driven diagnostic solutions and explore potential collaboration opportunities.
